Antiemetics Drugs Market Size, Share and Growth Outlook, 2026

Antiemetics Drugs Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Antiemetics Drugs Market size is forecast to increase from $9.62 Billion in 2026 to $15.1 Billion in 2034 at a CAGR of 5.8% between 2026 and 2034.

The Antiemetics Drugs market report provides detailed analysis and outlook of Antiemetics Drugs segments including By Drug Class (Serotonin, Dopamine Receptor Antagonists, Neurokinin-1, Corticosteroids, Cannabinoids, Antihistamines & Anticholinergics), By Indication (Chemotherapy-Induced Nausea and Vomiting, Post-Operative Nausea and Vomiting, Radiation-Induced Nausea and Vomiting, Motion Sickness & Vertigo, Gastroenteritis & Pregnancy-Related Emesis), By Route of Administration (Oral, Injectable / Parenteral, Transdermal Patches), By End-User (Hospitals & Clinics, Cancer Research & Infusion Centers, Ambulatory Surgical Centers, Home Care Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drugstores, Online Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Antiemetics Drugs Industry Overview

Novel Mechanisms of Action Expanding Motion Sickness Treatment Options

The antiemetics drugs industry is undergoing significant innovation with the introduction of new therapeutic classes targeting nausea and vomiting through highly specific biological pathways. A major milestone is the U.S. FDA approval of NEREUS™ (tradipitant) from Vanda Pharmaceuticals for the prevention of motion-induced vomiting in adults. This approval represents the first entirely new pharmacological class introduced for motion sickness prevention in more than four decades. Tradipitant, licensed from Eli Lilly and Company, functions as a highly selective oral neurokinin-1 (NK-1) receptor antagonist that blocks substance P binding within central nervous system pathways responsible for triggering emetic reflexes. The emergence of NK-1 receptor-targeted therapies highlights a growing industry focus on precision antiemetic treatments capable of delivering predictable and effective symptom control while addressing limitations associated with older antihistamines and anticholinergic therapies.

Expansion of Antiemetic Applications Beyond Traditional Indications

The antiemetics market is increasingly expanding into adjacent gastrointestinal and metabolic therapy segments as pharmaceutical companies seek broader clinical applications for established mechanisms. Following successful clinical performance in motion sickness prevention, tradipitant is advancing through Phase III development programs targeting gastroparesis and nausea and vomiting associated with GLP-1 receptor agonist therapies. The rapid growth of GLP-1-based treatments for obesity and metabolic disorders has created increasing demand for supportive medications that improve treatment tolerability and patient adherence. This trend is encouraging manufacturers to develop antiemetic therapies capable of addressing diverse causes of nausea and vomiting across neurological, gastrointestinal, metabolic, and treatment-related conditions. As patient populations requiring symptom management continue to expand, antiemetic drug developers are pursuing broader therapeutic indications and more specialized treatment approaches.

Veterinary Antiemetics Enhancing Companion Animal Care

The antiemetics industry also includes a growing veterinary segment focused on improving gastrointestinal care for companion animals. Dechra’s commercial rollout of Emeprev™ (maropitant citrate) Injectable Solution represents an important development within veterinary antiemetic therapeutics. As the first FDA-approved generic bioequivalent alternative to a widely used antiemetic agent, Emeprev is indicated for the prevention and treatment of acute vomiting in dogs and for the management of active vomiting in cats. The injectable formulation incorporates benzyl alcohol as a preservative, providing a mild local anesthetic effect that reduces injection-site discomfort and vocalization compared with traditional formulations. Additionally, the product eliminates the need for continuous refrigeration, improving storage convenience and operational efficiency for veterinary clinics. These advancements reflect the growing emphasis on enhanced patient comfort, accessibility, and treatment efficiency within the animal healthcare sector.

Antiemetics Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Antiemetics Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi S.A., Merck & Co., Inc., Helsinn Healthcare SA, Fresenius Kabi AG, Baxter International Inc., Sun Pharmaceutical Industries Ltd.. The Antiemetics Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Antiemetics Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Antiemetics Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Antiemetics Drugs companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Antiemetics Drugs markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Antiemetics Drugs Market Competitive Benchmarking and Company Analysis

Leading companies in Antiemetics Drugs industry include- GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi S.A., Merck & Co., Inc., Helsinn Healthcare SA, Fresenius Kabi AG, Baxter International Inc., Sun Pharmaceutical Industries Ltd.. The Antiemetics Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Antiemetics Drugs Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Antiemetics Drugs market remains one of the strongest-performing segments in the country.
The US Antiemetics Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Antiemetics Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Antiemetics Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Antiemetics Drugs markets

Canada's strong Antiemetics Drugs sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Antiemetics Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Antiemetics Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Antiemetics Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Antiemetics Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Antiemetics Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Antiemetics Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Antiemetics Drugs sales through 2034

France Antiemetics Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Antiemetics Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Antiemetics Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Antiemetics Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Antiemetics Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Antiemetics Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Antiemetics Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Antiemetics Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Antiemetics Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Antiemetics Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Antiemetics Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Antiemetics Drugs Market Segmentation

By Drug Class
Serotonin
Dopamine Receptor Antagonists
Neurokinin-1
Corticosteroids
Cannabinoids
Antihistamines & Anticholinergics
By Indication
Chemotherapy-Induced Nausea and Vomiting
Post-Operative Nausea and Vomiting
Radiation-Induced Nausea and Vomiting
Motion Sickness & Vertigo
Gastroenteritis & Pregnancy-Related Emesis
By Route of Administration
Oral
Injectable / Parenteral
Transdermal Patches
By End-User
Hospitals & Clinics
Cancer Research & Infusion Centers
Ambulatory Surgical Centers
Home Care Settings
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drugstores
Online Pharmacies

Top Companies in Antiemetics Drugs Industry

GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Merck & Co., Inc.
Helsinn Healthcare SA
Fresenius Kabi AG
Baxter International Inc.
Sun Pharmaceutical Industries Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025